Medinotec Q1 Revenue Jumps 24% to $2.65M, U.S. Sales Surge 87%
MDNC is trading near its 52-week low of $5 (0.0% above the low).
Summary
Medinotec's Q1 FY2027 revenue rose 24% to $2.65M, driven by an 87% surge in U.S. sales following the Outflo launch and recent FDA clearances. Net income nearly doubled to $222K, or $0.02 per share, aided by a tax benefit. Operating expenses jumped 77% to $1.13M as the company invested in selling and distributor support to accelerate market penetration. The U.S. commercial ramp is material for a company with a ~$59M market cap, though heavy customer concentration remains a risk. The 10-Q filed today provides the first detailed look at the U.S. expansion's impact.
At the time of this announcement, MDNC was trading at $5.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $58.8M. The 52-week trading range was $5.00 to $5.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.